Analysis of lipid-lowering therapy and factors affecting regularity of statin intake in patients with cardiovascular disease enrolled in the PROFILE registry

Revista Portuguesa de Cardiologia

Volumn 34, Issue 2, 2015, Pages 111-116

  Gaisenok, Oleg ^a,b   Martsevich, Sergey ^a,c   Tripkosh, Svetlana ^a   Lukina, Yulia ^a,c  

^a NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

^b FGBI Joint Hospital and Polyclinic Department of Presidential Affairs of the Russian Federation   (Russian Federation)

^c I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Compliance; Lipid lowering therapy; Registry; Statins

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIET; EXERCISE; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICATION COMPLIANCE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; RISK FACTOR; RUSSIAN FEDERATION; CARDIOVASCULAR DISEASES; COMPLICATION; REGISTER; SELF REPORT; STATISTICS AND NUMERICAL DATA;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MOSCOW; REGISTRIES; SELF REPORT;

EID: 84923070384     PISSN: 08702551     EISSN: 21742030     Source Type: Journal    
DOI: 10.1016/j.repc.2014.08.021     Document Type: Article

References (16)

1. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
2. LongTerm Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Eng J Med 339 1998 1349 1357
3. J.F. Plehn, B.R. Davis, and F.M. Sacks Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study Circulation 99 1999 216 223
4. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
5. West of Scotland Coronary Prevention Group West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials Lancet 348 1996 1339 1342
6. J.R. Downs, M. Clearfield, S. Weis for the AFCAPS/TexCAPS Research Group Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels JAMA 279 1998 1615 1622
7. P.S. Sever, B. Dahlof, and N.R. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
8. S. Yusuf, S. Islam, and C.K. Chow Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey Lancet 378 2011 1231 1243
9. A.V. Susekov, M.Yu. Zubareva, and A.D. Deev Main results of the Moscow Research on Statines (to Moscow Statin Survey, MSS) Serdce 2006 324 328
10. S.Yu. Martsevich, L.Yu. Drozdova, and N.P. Kutishenko Using registers to study effectiveness and safety of drugs Clinician 3-4 2012 4 9
11. S.Yu. Martsevich, M.L. Ginzburg, and N.P. Kutishenko The LIS study (Lubertsy study of mortality in patients with acute myocardial infarction). Evaluation of pharmacotherapy. Part 1. Treatment of patients before myocardial infarction and its influence on hospital mortality Rational Pharmacother Card 8 2012 681 684
12. N.M. Ivers, J.D. Schwalm, and C.A. Jackevicius Length of initial prescription at hospital discharge and long-term medication adherence for elderly patients with coronary artery disease: a population-level study Can J Cardiol 29 2013 1408 1414
13. V.G. Vimalananda, D.R. Miller, and T.P. Hofer Accounting for clinical action reduces estimates of gender disparities in lipid management for diabetic veterans J Gen Intern Med 28 Suppl 2 2013 S529 S535
14. D.J. Kumbhani, P.G. Steg, and C.P. Cannon Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis; REduction of Atherothrombosis for Continued Health Registry Investigators Am J Med 126 2013 693 700
15. J.R. Warren, M.O. Falster, and D. Fox Factors influencing adherence in long-term use of statins Pharmacoepidemiol Drug Saf 22 2013 1298 1307
16. J.D. Cohen, K.E. Aspry, and A.S. Brown Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop J Clin Lipidol 7 2013 573 609